AlQuraishi, Mohammed http://orcid.org/0000-0001-6817-1322
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54-CA225088)
United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-19-2-0022)
Article History
Received: 13 January 2021
Accepted: 27 August 2021
First Online: 4 October 2021
Competing interests
: P.K.S. is a member of the scientific advisory board or board of directors of Glencoe Software, Applied Biomath, RareCyte and NanoString and a consultant to Montai Health and Merck; he has equity in several of these companies. P.K.S. declares that none of these relationships are directly or indirectly related to the content of this manuscript. M.A.Q. is a member of the scientific advisory board of FL2021-002, a Foresite Labs company, and consults for Interline Therapeutics.